Elizabeth Griffiths, MD, associate professor of oncology, department of medicine, Roswell Park Comprehensive Cancer Center discusses which biomarkers and mutational events help determine if a patient would likely benefit from a traditional therapy or if they are more suitable for a clinical trial or upfront allogeneic transplantation.
Elizabeth Griffiths, MD, associate professor of oncology, department of medicine, Roswell Park Comprehensive Cancer Center discusses which biomarkers and mutational events help determine if a patient would likely benefit from a traditional therapy or if they are more suitable for a clinical trial or upfront allogeneic transplantation.
TranscriptWhich biomarkers or mutational events help determine if a patient with acute myeloid leukemia (AML) would likely benefit from a traditional therapy or if they are more suitable for a clinical trial or upfront allogeneic transplantation?
I think the majority of us in the community would say that patients with complex karyotype or p53 mutant disease tend to fare less well with traditional induction approaches. I think in that patient population, I would be more likely to think about giving them a liposomal cytarabine and daunorubicin combination strategy, or even an alternative induction like a combination of azacitidine and venetoclax or decitabine and venetoclax.
Since their molecular profile tends to predict a poor response to standard therapy and, at least with the data that Daniel Pollyea, MD, MS, associate professor of medicine, University of Colorado School of Medicine, is going to present tomorrow, it seems as though those patients do a little bit better with this alternative combination strategy.
I don’t think that’s really ready to prime time, and I don’t think that’s supported, necessarily, by well-controlled data, but it’s certainly a feeling that many of us I think in the field have. If you have a young fit patient, I think one is compelled to really think strongly and offer the patient standard induction therapy, even if they have relatively poor-risk mutational features or cytogenetic risk profile, possibly with a combination of the liposomal combination therapy, since that appears to result in a better long-term outcome, especially in patients who are eligible for allogeneic transplant. And that would be the kind of patient where you would want to be able to offer an upfront allogeneic transplant.
With respect to upfront allogeneic transplant, I don’t think we would do that for patients with overt leukemic disease, unless they had really exhausted all other strategies. So, I wouldn’t do it upfront, but I might consider it if I have a patient who I’m able to get into a good, deep complete remission who has a high risk of relapse.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Kathy Oubre on Strategies to Mitigate Challenges When Adopting New Payment Models
February 23rd 2024While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.
Read More
Getting to Know Dr Shauna Downs, Public Health Nutritionist
February 23rd 2024Shauna Downs, PhD, MS, is an associate professor in the Department of Health Behavior, Society, and Policy at the Rutgers School of Public Health. A former figure skater, her research now focuses on interventions to promote healthy and sustainable food choices and exploring how our changing climate, food systems, diet, and nutrition are inextricably linked.
Read More